Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140

Journal of Virology

Volumn 75, Issue 2, 2001, Pages 579-588

  Trkola, A ^a   Ketas, T J ^a   Nagashima, K A ^a   Zhao, L ^a   Cilliers, T ^a   Morris, L ^a   Moore, J P ^a   Maddon, P J ^a   Olson, W C ^a  

^a A Subsidiary of Lantheus Holdings   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; MONOCLONAL ANTIBODY; PRO 140; RANTES; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOTHERAPY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS REPLICATION;

AMIDES; AMINO ACID SEQUENCE; ANTI-HIV AGENTS; ANTIBODIES, MONOCLONAL; BASE SEQUENCE; CELLS, CULTURED; GENE PRODUCTS, ENV; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MACROPHAGES; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; QUATERNARY AMMONIUM COMPOUNDS; RANTES; RECEPTORS, CCR5; VIRUS REPLICATION;

EID: 0035173073     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.2.579-588.2001     Document Type: Article

References (78)

1. HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS
2. The inhibitory effect of RANTES on the infection of primary macrophages by R5 human immunodeficiency virus type-1 depends on the macrophage activation state
3. HIV blocked by chemokine antagonist
4. Resistance of primary isolates of human immunodeficiency virus type 1 to soluble CD4 is independent of CD4-rgp120 binding affinity
5. Multiple extracellular elements of CCR5 and HIV-1 entry: Dissociation from response to chemokines
6. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity
7. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques
8. Homozygous delta 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient
9. Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5Δ32
10. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease
11. HIV-1 infection in an individual homozygous for the CCR5 deletion allele
12. Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients
13. 2+ signaling
14. Identification of RANTES, MIP-1α, and MIP-1β as the major HIV-suppressive factors produced by CD8+ T cells
15. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals
16. Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120
17. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene
18. CC chemokine receptor 5 cell-surface expression in relation to CC chemokine receptor 5 genotype and the clinical course of HIV-1 infection
19. Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for human immunodeficiency virus type 1 disease progression
20. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5
21. Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry
22. A binding pocket for a small molecule inhibitor of H1V-1 entry within the transmembrane helices of CCRS
23. Human immunodeficiency viruses in the developing world
24. HIV-1 entry and macrophage inflammatory protein-1β-mediated signaling are independent functions of the chemokine receptor CCR5
25. A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCRS
26. CCR5-mediated human immunodeficiency virus entry depends on an amino-terminal gp120-binding site and on the conformational integrity of all four extra-cellular domains
27. Preferential coreceptor utilization and cytopathicity by dual-tropic HIV-1 in human lymphoid tissue ex vivo
28. Enhancement of human immunodeficiency virus type 1 infection by the CC-chemokine RANTES is independent of the mechanism of virus-cell fusion
29. Molecular uncoupling of C-C chemokine receptor 5-induced chemotaxis and signal transduction from HIV-1 coreceptor activity
30. Inhibition of in vitro and in vivo HIV replication by a distamycin analogue that interferes with chemokine receptor function: A candidate for chemotherapeutic and microbicidal application
31. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression
32. Relationship between productive HIV-1 infection of macrophages and CCR5 utilization
33. Analysis of the critical domain in the V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization
34. Association between CCR5 genotype and the clinical course of HIV-1 infection
35. + T cells: Role of signal transduction
36. A polymorphism in the regulatory region of the CC-chemokine receptor 5 gene influences perinatal transmission of human immunodeficiency virus type 1 to African-American infants
37. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function
38. Coreceptor competition for association with CD4 may change the susceptibility of human cells to infection with T-tropic and macrophagetropic isolates of human immunodeficiency virus type 1
39. Persistent CCR5 utilization and enhanced macrophage tropism by primary blood human immunodeficiency virus type 1 isolates from advanced stages of disease and comparison to tissue-derived isolates
40. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: A novel inhibitory mechanism of HIV infectivity
41. Genetic acceleration of AIDS progression by a promoter variant of CCR5
42. CCR5 promoter polymorphism and HIV-1 disease progression
43. Inhibition of human immunodeficiency virus fusion by a monoclonal antibody to a coreceptor (CXCR4) is both cell type and virus strain dependent
44. The LD78β isoform of MIP-1α is the most potent CCR5 agonist and HIV-1-inhibiting chemokine
45. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression
46. HIV-1 entry inhibitors: Evading the issue
47. CCR5 chemokine receptor variant in HIV-1 mother-to-child transmission and disease progression in children
48. CD8+ T-cell-derived soluble factor(s), but not beta-chemokines RANTES, MIP-1α and MIP-1β, suppress HIV-1 replication in monocyte/macrophages
49. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression
50. HIV-1 infection in a man homozygous for CCR5 delta 32
51. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5
52. Beta-chemokine inhibition of monocytotropic HIV-1 infection. Interference with a postbinding fusion step
53. Regulation of anti-HIV-1 activity of RANTES by heparan sulfate proteoglycans
54. Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: Underrepresentation of X4 variants
55. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1
56. Alanine substitutions of polar and nonpolar residues in the amino-terminal domain of CCR5 differently impair entry of macrophage- and dualtropic isolates of human immunodeficiency virus type 1
57. Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120
58. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding
59. Chemokines and HIV replication
60. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist
61. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression
62. Strategies for AIDS vaccines
63. HIV-1 infection in an individual homozygous for CCR5 delta 32
64. Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs
65. Cross-clade neutralization of primary isolates of human immunodeficiency virus type I by human monoclonal antibodies and tetrameric CD4-IgG
66. The CC-chemokine RANTES increases the attachment of human immunodeficiency vires type 1 to target cells via glycosaminoglycans and also activates a signal transduction pathway that enhances viral infectivity
67. Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage
68. A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor
69. Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines
70. Differences in chemokine coreceptor usage between genetic subtypes of HIV-1
71. Expression of CCR5 increases during monocyte differentiation and directly mediates macrophage susceptibility to infection by human immunodeficiency virus type 1
72. Beta-chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteo-glycans
73. CCR5 levels and expression pattern correlate with infectability by macrophagetropic HIV-1, in vitro
74. Interaction of chemokine receptor CCR5 with its ligands: Multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding
75. Constitutive cell surface association between CD4 and CCR5
76. CXCR-4 is expressed by primary macrophages and supports CCR5-independent infection by dual-tropic but not T-tropic isolates of human immunodeficiency virus type 1
77. Synthetic full-length and truncated RANTES inhibit HIV-1 infection of primary macrophages
78. Use of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro